{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:05:23Z","timestamp":1790888723327,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.japh.2022.04.014","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T12:32:27Z","timestamp":1650976347000},"page":"1596-1605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacist-led drug therapy management for hepatitis C at a federally qualified health care center"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-4181","authenticated-orcid":false,"given":"Jessica M.","family":"Downes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4883-0911","authenticated-orcid":false,"given":"Anthony","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7315-6896","authenticated-orcid":false,"given":"Carrie","family":"McAdam-Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.japh.2022.04.014_bib1","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"issue":"108025","key":"10.1016\/j.japh.2022.04.014_bib2","first-page":"1","article-title":"Hepatitis C cascade of care at an integrated community facility for people who inject drugs","volume":"114","author":"Morris","year":"2020","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"2","key":"10.1016\/j.japh.2022.04.014_bib3","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/jim-2020-001521","article-title":"Linkage to specialty care in the hepatitis C care cascade","volume":"69","author":"Blanding","year":"2021","journal-title":"J\u00a0Investig Med"},{"issue":"2","key":"10.1016\/j.japh.2022.04.014_bib4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2105\/AJPH.2015.302927","article-title":"Cascade of care for hepatitis C virus infection within the US Veterans Health Administration","volume":"106","author":"Maier","year":"2016","journal-title":"Am J Public Health"},{"issue":"11","key":"10.1016\/j.japh.2022.04.014_bib5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1473-3099(12)70177-9","article-title":"Prevalence of tuberculosis, hepatitis C virus, and HIV in homeless people: a systematic review and meta-analysis","volume":"12","author":"Beijer","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"19","key":"10.1016\/j.japh.2022.04.014_bib6","doi-asserted-by":"crossref","first-page":"569","DOI":"10.15585\/mmwr.mm6919a1","article-title":"High prevalence of hepatitis C infection among adult patients at four urban emergency departments - Birmingham, Oakland, Baltimore, and Boston, 2015\u20132017","volume":"69","author":"Galbraith","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1016\/j.japh.2022.04.014_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/MOG.0000000000000520","article-title":"Population-based screening of hepatitis C virus in the United States","volume":"35","author":"Bian","year":"2019","journal-title":"Curr Opin Gastroenterol"},{"issue":"2","key":"10.1016\/j.japh.2022.04.014_bib8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jval.2021.08.006","article-title":"Time costs and out-of-pocket costs in chronic hepatitis C patients in a publicly funded health system","volume":"25","author":"Wong","year":"2022","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.japh.2022.04.014_bib9","first-page":"6","article-title":"Hepatitis C virus infection screening within community health centers","volume":"116","author":"Cook","year":"2016","journal-title":"J\u00a0Am Osteopath Assoc"},{"issue":"9","key":"10.1016\/j.japh.2022.04.014_bib10","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/01.mcg.0000177258.95562.43","article-title":"High rates of uninsured among HCV-positive individuals","volume":"39","author":"Ong","year":"2005","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"6","key":"10.1016\/j.japh.2022.04.014_bib12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/jvh.12669","article-title":"A systematic model improves hepatitis C virus birth cohort screening in hospital-based primary care","volume":"24","author":"Goel","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"issue":"7","key":"10.1016\/j.japh.2022.04.014_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102883","article-title":"The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care","volume":"9","author":"Cachay","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.japh.2022.04.014_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/hep.30638","article-title":"Evaluation of a multifaceted intervention to reduce health disparities in hepatitis C screening: a pre-post analysis","volume":"70","author":"Jain","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.japh.2022.04.014_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/1178633719841381","article-title":"Integration of hepatitis C treatment in a primary care federally qualified health center; Philadelphia, Pennsylvania, 2015\u20132017","volume":"12","author":"Bartholomew","year":"2019","journal-title":"Infect Dis (Auckl)"},{"issue":"6","key":"10.1016\/j.japh.2022.04.014_bib16","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1053\/j.gastro.2017.10.016","article-title":"Cost-effectiveness of access expansion to treatment of hepatitis C virus infection through primary care providers","volume":"153","author":"Rattay","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.japh.2022.04.014_bib17","article-title":"A\u00a0regional analysis of hepatitis C virus collaborative care with pharmacists in Indian Health Service facilities","volume":"9","author":"Geiger","year":"2018","journal-title":"J\u00a0Prim Care Community Health"},{"issue":"3","key":"10.1016\/j.japh.2022.04.014_bib18","first-page":"364","article-title":"Outcomes of pharmacy-led hepatitis C direct-acting antiviral utilization management at a Veterans Affairs Medical Center","volume":"23","author":"Yang","year":"2017","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"10","key":"10.1016\/j.japh.2022.04.014_bib19","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.japh.2022.04.014_bib35","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/hep.29362","article-title":"Impact of an electronic health record alert in primary care on increasing hepatitis c screening and curative treatment for baby boomers","volume":"66","author":"Konerman","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.japh.2022.04.014_bib20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/JHQ.0000000000000010","article-title":"Improving hepatitis C virus screening rates in primary care: a targeted intervention using the electronic health record","volume":"37","author":"Sidlow","year":"2015","journal-title":"J\u00a0Healthc Qual"},{"issue":"2","key":"10.1016\/j.japh.2022.04.014_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","article-title":"CDC recommendations for hepatitis C screening among adults - United States, 2020","volume":"69","author":"Schillie","year":"2020","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"10.1016\/j.japh.2022.04.014_bib22","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s11606-020-05701-9","article-title":"HCV testing and treatment in a national sample of US federally qualified health centers during the opioid epidemic","volume":"35","author":"Assoumou","year":"2020","journal-title":"J\u00a0Gen Intern Med"},{"issue":"1","key":"10.1016\/j.japh.2022.04.014_bib23","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12879-020-05103-6","article-title":"Clients\u2019 perceptions of barriers and facilitators to implementing hepatitis C virus care in homeless shelters","volume":"20","author":"Masson","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"44","key":"10.1016\/j.japh.2022.04.014_bib24","doi-asserted-by":"crossref","first-page":"7846","DOI":"10.3748\/wjg.v19.i44.7846","article-title":"Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care","volume":"19","author":"Zeremski","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.japh.2022.04.014_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13722-021-00260-8","article-title":"\u2018Treat my whole person, not just my condition\u2019: qualitative explorations of hepatitis C care delivery preferences among people who inject drugs","volume":"16","author":"Tsui","year":"2021","journal-title":"Addict Sci Clin Pract"},{"issue":"27","key":"10.1016\/j.japh.2022.04.014_bib26","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.japh.2022.04.014_bib27","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/hep.28422","article-title":"Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2)","volume":"64","author":"Lawitz","year":"2016","journal-title":"Hepatology"},{"issue":"20","key":"10.1016\/j.japh.2022.04.014_bib28","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.japh.2022.04.014_bib29","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1007\/s12325-020-01449-0","article-title":"Real-world clinical practice use of 8-week Glecaprevir\/Pibrentasvir in treatment-na\u00efve patients with compensated cirrhosis","volume":"37","author":"Lampertico","year":"2020","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.japh.2022.04.014_bib30","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1007\/s40121-021-00455-1","article-title":"Real-world outcomes in historically underserved patients with chronic hepatitis C infection treated with Glecaprevir\/Pibrentasvir","volume":"10","author":"Aghemo","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"8","key":"10.1016\/j.japh.2022.04.014_bib32","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s10620-017-4608-9","article-title":"Primary care and hepatology provider-perceived barriers to and facilitators of hepatitis C treatment candidacy and adherence","volume":"62","author":"Rogal","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.japh.2022.04.014_bib33","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1186\/s12889-020-09000-0","article-title":"Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators","volume":"20","author":"Serumondo","year":"2020","journal-title":"BMC Public Health"},{"issue":"5","key":"10.1016\/j.japh.2022.04.014_bib34","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s10620-019-05877-z","article-title":"Provider perceptions of hepatitis C treatment adherence and initiation","volume":"65","author":"Zhang","year":"2020","journal-title":"Dig Dis Sci"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122001327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122001327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:50:46Z","timestamp":1761544246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319122001327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1544319122001327"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2022.04.014","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacist-led drug therapy management for hepatitis C at a federally qualified health care center","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2022.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}